The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. 1984

D A Leigh, and F X Emmanuel

Norfloxacin, a new quinolone compound has marked activity against strains of Pseudomonas aeruginosa being superior to that of gentamicin, carbenicillin, ticarcillin, the ureidopenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying uripenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying uripenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying urinary tract disease. The other failure was due to a resistant strain of Ps. aeruginosa. Norfloxacin is a new valuable oral antimicrobial agent with a wide range of bacterial activity which includes many strains of bacteria resistant to other agents. Due to its high urinary concentrations, norfloxacin is particularly indicated in the treatment of urinary tract infections.

UI MeSH Term Description Entries
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009268 Nalidixic Acid A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE. Nalidixin,Nalidixate Sodium,Nalidixate Sodium Anhydrous,Nevigramon,Sodium Nalidixic Acid, Anhydrous,Sodium Nalidixic Acid, Monohydrate,Acid, Nalidixic,Anhydrous, Nalidixate Sodium,Sodium Anhydrous, Nalidixate,Sodium, Nalidixate
D009643 Norfloxacin A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE. AM-0715,AM-715,MK-0366,MK-366,MK0366,MK366,Noroxin,AM 0715,AM 715,AM0715,MK 0366,MK 366
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000892 Anti-Infective Agents, Urinary Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. Antiseptics, Urinary,Antiinfective Agents, Urinary,Urinary Anti-Infective Agents,Urinary Antiinfective Agents,Agents, Urinary Anti-Infective,Agents, Urinary Antiinfective,Anti Infective Agents, Urinary,Urinary Anti Infective Agents,Urinary Antiseptics
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

D A Leigh, and F X Emmanuel
October 1982, JAMA,
D A Leigh, and F X Emmanuel
January 1984, Reviews of infectious diseases,
D A Leigh, and F X Emmanuel
May 1986, Wiener klinische Wochenschrift,
D A Leigh, and F X Emmanuel
October 1983, JAMA,
D A Leigh, and F X Emmanuel
October 1991, Nihon rinsho. Japanese journal of clinical medicine,
D A Leigh, and F X Emmanuel
January 1982, Scandinavian journal of infectious diseases,
D A Leigh, and F X Emmanuel
June 1983, The New Zealand medical journal,
D A Leigh, and F X Emmanuel
May 1978, Nihon rinsho. Japanese journal of clinical medicine,
D A Leigh, and F X Emmanuel
August 2007, Harefuah,
D A Leigh, and F X Emmanuel
February 1994, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Copied contents to your clipboard!